Eight Adani Group companies settle with gains; Adani Enterprises rallies 5 per cent
时间:2024-09-29 04:25:55 阅读(143)
Stocks of eight listed Adani Group firms settled with gains on Monday and Adani Enterprises rose more than 5 per cent amid positive momentum in the broader equity market.
Some of the group stocks also hit their upper circuit levels.
The market valuation of the flagship firm rose to Rs 2.26 lakh crore.
Shares of Adani Power, Adani Transmission, Adani Energy, Adani Total Gas and Adani Wilmar jumped 5 per cent each and their closing levels touched the respective upper price bands on the BSE.
Also, shares of NDTV climbed 4.95 per cent and Adani Ports and Special Economic Zone gained nearly 1 per cent.
However, shares of Ambuja Cements declined 1.65 per cent and ACC fell 1.50 per cent.
The 30-share BSE Sensex zoomed 415.49 points or 0.69 per cent to settle at 60,224.46 points. The NSE Nifty rose 117.10 points or 0.67 per cent to 17,711.45 points.
On Friday, shares of all listed Adani Group companies rallied after the group sold minority stakes in four of its listed companies to US-based GQG Partners for Rs 15,446 crore.
After taking a beating on the bourses following the report by US-based short seller Hindenburg Research, the group stocks have recovered significantly in the last few trading sessions.
The report had made a litany of allegations, including fraudulent transactions and share-price manipulation, against it.
The group has dismissed the charges as lies, saying it complies with all laws and disclosure requirements.
猜你喜欢
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
- Import duty waiver for tur & urad extended till end of FY25
- BITS Pilani and Gati Shakti Vishwavidyalaya form alliance for research and education
- Bond yield rises further ahead of weekly auction
- FedFina board revives IPO plan
- FII, DII data- FPIs sold shares worth Rs 1761 Cr, DIIs added shares worth Rs 1328 Cr on October 30, Monday
- Budget 2023- Googly on capital gains leaves experts stumped, HNIs sweat
- Imprisoned Russian opposition leader Navalny located in penal colony 3 weeks after contact lost
- Bihar triple murder- Woman, husband and 2-year-old daughter killed by family in suspected honour killing